Interest of PET-PSMA Imaging Potentialised by Androgen Blockade in Localized Prostatic Adenocarcinoma

Prostate Adenocarcinoma Clinical Trial

— PREFAcE  

Official title:

Interest of PET-PSMA Imaging Potentiated by Androgen Blockade in Patients With Biological Relapse or Persistent Biological Disease of a Localized Prostatic Adenocarcinoma After Initial Treatment

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04391556
• Other study ID #: ET19-194 - PREFAcE
• Status: Recruiting
• Phase: Phase 2
• Start date: September 14, 2020
• Est. completion date: March 14, 2024

Study information

• Verified date: March 2022
• Source: Centre Leon Berard
• Contact: Séverine METZGER
• Phone: +33 4 78 78 27 86
• Email: severine.metzger[@]lyon.unicancer.fr
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Evaluation of the interest of PET-PSMA imaging potentiated by androgen blockade in patients with biological relapse or persistent biological disease of a localized prostatic adenocarcinoma after initial treatment

Description:

The identification of lesions responsible for biological recurrence or persistent biological disease in patients with prostatic adenocarcinoma (PA) remains an outstanding problem due to the lack of sensitivity of standard imaging techniques. The efficacy of empirical radiation therapy of the prostate + pelvis zone in only half of patients with increased PSA suggests an underestimation of lesions. PET-68Ga-PSMA or PET-PSMA technique showed a clear gain in sensitivity for the detection of lesions in this context compared to PET-Choline which was already more sensitive than standard imaging. It is about 50% for a PSA <0.5 ng / ml vs 20% for a PSA <1 ng / ml for TEP-Choline technique. However, the indication of empirical radiotherapy is raised when the PSA exceeds 0.2 ng / ml. It is therefore still necessary to increase the sensitivity of PET-PSMA. A flare-up-related effect was observed in a small animal experiment and in a patient after androgen blocking treatment, inducing a sharp increase in the intensity of previously visualized lesions and the appearance of 13 new lesions. It would therefore be possible to increase the expression of PSMA by the lesions at the origin of the biological recurrence of AP and thus to improve their detection by PET-PSMA after potentiation by short-term androgen blocking by an antagonist of LH-RH.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 52
• Est. completion date: March 14, 2024
• Est. primary completion date: March 29, 2023
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age = 18 years old;
• Hormone-naive patients, initially treated curatively by prostatectomy for prostate adenocarcinoma and having a first or new biological recurrence (PSA greater than 0.2 ng/ml; confirmed on at least two successive dosages in the last 12 months) OR Hormone-naive patients, initially treated curatively by external radiotherapy or by brachytherapy for prostate adenocarcinoma and having a biological recurrence (PSA Nadir + 2ng/ml ; confirmed on at least two successive dosages in the last 12 months ) OR hormone-naive patients treated by surgery or external radiotherapy or brachytherapy for prostate adenocarcinoma but with persistent biological disease (PSA detectable after prostatectomy, or unchanged or increasing PSA after external radiotherapy or brachytherapy);
• Diagnostic recurrence assessment by any information or examination carried out since the ascension of the PSA, not having revealed local recurrence or lymph node lesions which may benefit from to external radiation
• Signed informed consent.

Exclusion Criteria:

• Patient already treated by hormonotherapy;
• Formal contraindication to hormonotherapy;
• Formal contraindication to external radiotherapy
• Formal contraindication to the Lasilix administration during the PET exams:

Hypersensitivity to Furosemide or to one of the excipients, functional acute renal insufficiency, hepatic encephalopathy, urinary tracts obstruction, hypovolemia or dehydration, severe hypokalemia, severe hyponatremia, hepatitis in evolution and severe hepatocellular insufficiency in haemodialysis patient and patient presenting a severe renal insufficiency (creatinine clearance <30 ml / min) due to the risk of accumulation of furosemide, which is then mainly eliminated by the biliary route;

• Significant cardiovascular affection such as myocardial infarction within the last 6 months preceding inclusion, severe rhythm disturbances, stroke within 6 months prior to inclusion, prolonged corrected QT interval with QTc > 450 msecs according to Bazett formula;
• Impossibility to comply with the study follow-up for geographical or psychic reasons.
• Patient under protection of justice (Under tutorship, curatorship or deprived of liberty)

Related Conditions & MeSH terms

• Adenocarcinoma
• Prostate Adenocarcinoma

Intervention

Drug:
• Firmagon
120 mg subcutaneous Injection of Firmagon after a TEP-PSMA

Locations

Country	Name	City	State
France	Centre Jean Perrin	Clermont-Ferrand
France	Chu Gabriel Montpied	Clermont-Ferrand
France	Centre Hospitalier de Grenoble Hôpital Nord Michallon	La Tronche
France	Centre Léon Bérard	Lyon
France	APHM - Hôpital Nord	Marseille
France	Centre Hospitalier Lyon Sud	Pierre-Bénite

Sponsors (1)

Lead Sponsor	Collaborator
Centre Leon Berard

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	In case of envisaged irradiation, impact on the modifications of irradiation volumes between the initial PET-PSMA and the PET-PSMA-H	PET-PSMA and PET-PSMA-H	Day 14 after the androgenic blockade
Primary	Comparison of the proportion of patients presenting a positive PET during the initial PSMA-PET (prior to androgenic blockade) and the PSMA-H-PET (PSMA PET after androgenic blockade), patient being his own witness	PSMA-PET	Day 14 after the androgenic blockade
Secondary	Evaluation of the reproductibility of the PSMA-PET and PSMA-H-PET interpretation	PSMA-PET and PSMA-H-PET	Day 14 after the androgenic blockade
Secondary	Evaluation of the impact of androgenic blockade on lesions revealed by PSMA-H PET in comparison with the initial PSMA-PET	Number of lesions (PSMA-ET and PSMA-H PET)	Day 14 after the androgenic blockade
Secondary	Evaluation of the impact of androgenic blockade on lesions revealed by PSMA-H PET in comparison with the initial PSMA-PET	Fixation intensity (PSMA-ET and PSMA-H PET)	Day 14 after the androgenic blockade
Secondary	Evaluation of the PSMA-PET and PSMA-H PET impact in the therapeutic management modifications	Comparison between treatments planned after PSMA-PET and treatments planned after PSMA-H-PET	Day 14 after the androgenic blockade
Secondary	Evaluation of the interest of late pelvic acquisition 3 hours after the PSMA-68Ga injection	PSMA-PET and PSMA-H-PET efficience	Day 14 after the androgenic blockade
Secondary	Evaluation of the results correlation of each PSMA-PET with clinical data, histologic primary tumor and biologic data of the recurrence (PSA kinetic and velocity assessed at screening)	PSMA-PET efficience	Day 14 after the androgenic blockade
Secondary	Evaluation of the results correlation of each PSMA-PET with clinical data, histologic primary tumor and biologic data of the recurrence (PSA kinetic and velocity assessed at screening)	PSA rate	Day 14 after the androgenic blockade
Secondary	Evaluation of the correlation between the PSA and testosterone rates variations between D0 and D14 and the PSMA-PET results	PSA and testosterone rates and PSMA-PET results	Day 14 after the androgenic blockade
Secondary	Tolerance profile	Incidence of PSMA-H-PET Adverse Events assessed by the Common Terminology Criteria for Adverse Events (CTCAE version 5.0)	Up to Day 15-30 visit